RecruitingNCT06883214

Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application

Deciphering the Functional Role of a Three-miRNA Signature in Glioma: From Molecular Mechanisms to Potential Clinical Application


Sponsor

Regina Elena Cancer Institute

Enrollment

10 participants

Start Date

Jan 17, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Individual overexpression of the three miRNAs negatively affects cell viability and proliferation mainly in grade III IDH-wild type cells, while in higher grade cells, the effect is more pronounced when the entire signature is overexpressed, individual and combined overexpression of the signature members is able to determine a significant reduction in both migration and invasion. Therefore, ectopic expression of the miRNAs identified by us has a negative impact on cell viability, proliferation and apoptosis, but above all on migration and invasion.


Eligibility

Inclusion Criteria5

  • histological diagnosis of glioma;
  • no concomitant primary tumor;
  • no metastatic disease;
  • availability of surgical material/tissue;
  • written informed consent.

Exclusion Criteria5

  • histological diagnosis of non-glial tumor;
  • patients with concomitant other solid tumors;
  • metastatic disease;
  • no surgical material/tissue available;
  • HIV seropositivity.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

"Regina Elena" National Cancer Institute

Rome, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06883214


Related Trials